Subversion of cytokine networks by virally encoded decoy receptors

Immunological Reviews

Volumn 250, Issue 1, 2012, Pages 199-215

  Epperson, Megan L ^a   Lee, Chung A ^a   Fremont, Daved H ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Decoy receptor; Herpesvirus; Immune evasion; Poxvirus; Pro inflammatory cytokines; Structural immunology; Viral mimicry

Indexed keywords

CHEMOKINE; CHEMOKINE BINDING PROTEIN; CHEMOKINE RECEPTOR; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 1; INTERLEUKIN 18; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; RANTES; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2; UNCLASSIFIED DRUG;

ARTICLE; CHORDOPOXVIRINAE; HERPES SIMPLEX; HUMAN; IMMUNOMODULATION; IMMUNOSURVEILLANCE; NONHUMAN; POXVIRUS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN STRUCTURE; VIRUS PATHOGENESIS;

CHEMOKINES; HERPESVIRIDAE; HERPESVIRIDAE INFECTIONS; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNE EVASION; IMMUNOLOGIC SURVEILLANCE; MOLECULAR MIMICRY; POXVIRIDAE; POXVIRIDAE INFECTIONS; RECEPTORS, CHEMOKINE; RECEPTORS, VIRUS; SIGNAL TRANSDUCTION; VIRAL PROTEINS;

EID: 84867411780     PISSN: 01052896     EISSN: 1600065X     Source Type: Journal    
DOI: 10.1111/imr.12009     Document Type: Article

References (168)

1. Janeway CA, Jr. How the immune system protects the host from infection. Microbes Infect 2001;3:1167-1171.
2. Guidotti LG, Chisari FV. Noncytolytic control of viral infections by the innate and adaptive immune response. Annu Rev Immunol 2001;19:65-91.
3. Medzhitov R, Janeway CA, Jr. Innate immune induction of the adaptive immune response. Cold Spring Harb Symp Quant Biol 1999;64:429-435.
4. Rossi D, Zlotnik A. The biology of chemokines and their receptors. Annu Rev Immunol 2000;18:217-242.
5. Seet BT, et al. Poxviruses and Immune Evasion. Annu Rev Immunol 2003;21:377-423.
6. Alcami A, Koszinowski UH. Viral mechanisms of immune evasion. Trends Microbiol 2000;8:410-418.
7. Unterholzner L, Bowie AG. The interplay between viruses and innate immune signaling: recent insights and therapeutic opportunities. Biochem Pharmacol 2008;75:589-602.
8. Kotenko SV, Saccani S, Izotova LS, Mirochnitchenko OV, Pestka S. Human cytomegalovirus harbors its own unique IL-10 homolog (cmvIL-10). Proc Natl Acad Sci USA 2000;97:1695-1700.
9. Ding Y, Qin L, Kotenko SV, Pestka S, Bromberg JS. A single amino acid determines the immunostimulatory activity of interleukin 10. J Exp Med 2000;191:213-224.
10. Haig DM, Fleming S. Immunomodulation by virulence proteins of the parapoxvirus orf virus. Vet Immunol Immunopathol 1999;72:81-86.
11. Moore PS, Boshoff C, Weiss RA, Chang Y. Molecular mimicry of human cytokine and cytokine response pathway genes by KSHV. Science 1996;274:1739-1744.
12. Yao Z, et al. Herpesvirus Saimiri encodes a new cytokine, IL-17, which binds to a novel cytokine receptor. Immunity 1995;3:811-821.
13. Lalani AS, McFadden G. Evasion and exploitation of chemokines by viruses. Cytokine Growth Factor Rev 1999;10:219-233.
14. Lusso P. Chemokines and viruses: the dearest enemies. Virology 2000;273:228-240.
15. Chow D, He X, Snow AL, Rose-John S, Garcia KC. Structure of an extracellular gp130 cytokine receptor signaling complex. Science 2001;291:2150-2155.
16. Chatterjee M, Osborne J, Bestetti G, Chang Y, Moore PS. Viral IL-6-induced cell proliferation and immune evasion of interferon activity. Science 2002;298:1432-1435.
17. Comeau MR, et al. A poxvirus-encoded semaphorin induces cytokine production from monocytes and binds to a novel cellular semaphorin receptor, VESPR. Immunity 1998;8:473-482.
18. Liu H, et al. Structural basis of semaphorin-plexin recognition and viral mimicry from Sema7A and A39R complexes with PlexinC1. Cell 2010;142:749-761.
19. Murphy PM. Viral exploitation and subversion of the immune system through chemokine mimicry. Nat Immunol 2001;2:116-122.
20. McFadden G, Murphy PM. Host-related immunomodulators encoded by poxviruses and herpesviruses. Curr Opin Microbiol 2000;3:371-378.
21. Murphy PM. Molecular mimicry and the generation of host defense protein diversity. Cell 1993;72:823-826.
22. Fields BN, Knipe DM, Howley PM. Fields Virology [Electronic Resource]. 5th edn. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins, 2007.
23. Engel P, Angulo A. Viral immunomodulatory proteins: usurping host genes as a survival strategy. Adv Exp Med Biol 2012;738:256-276.
24. Alcamí A, Smith GL. A soluble receptor for interleukin-1 beta encoded by vaccinia virus: a novel mechanism of virus modulation of the host response to infection. Cell 1992;71:153-167.
25. Alcamí A, Smith GL. Vaccinia, cowpox, and camelpox viruses encode soluble gamma interferon receptors with novel broad species specificity. J Virol 1995;69:4633-4639.
26. Chen N, Buller RM, Wall EM, Upton C. Analysis of host response modifier ORFs of ectromelia virus, the causative agent of mousepox. Virus Res 2000;66:155-173.
27. Symons JA, Alcamí A, Smith GL. Vaccinia virus encodes a soluble type I interferon receptor of novel structure and broad species specificity. Cell 1995;81:551-560.
28. Lau EK, Allen S, Hsu AR, Handel TM. Chemokine-receptor interactions: GPCRs, glycosaminoglycans and viral chemokine binding proteins. Adv Protein Chem 2004;68:351-391.
29. Middleton J, Patterson AM, Gardner L, Schmutz C, Ashton BA. Leukocyte extravasation: chemokine transport and presentation by the endothelium. Blood 2002;100:3853-3860.
30. Proudfoot AEI, et al. Glycosaminoglycan binding and oligomerization are essential for the in vivo activity of certain chemokines. Proc Natl Acad Sci USA 2003;100:1885-1890.
31. Ono SJ, Nakamura T, Miyazaki D, Ohbayashi M, Dawson M, Toda M. Chemokines: roles in leukocyte development, trafficking, and effector function. J Allergy Clin Immunol 2003;111:1185-1199; quiz 1200.
32. Thelen M. Dancing to the tune of chemokines. Nat Immunol 2001;2:129-134.
33. Mellado M. Martínez-AC, Rodríguez-Frade JM. Analysis of G-protein-coupled receptor dimerization following chemokine signaling. Methods 2002;27:349-357.
34. Sánchez-Madrid F, del Pozo MA. Leukocyte polarization in cell migration and immune interactions. EMBO J 1999;18:501-511.
35. Kledal TN, et al. A broad-spectrum chemokine antagonist encoded by Kaposi's sarcoma-associated herpesvirus. Science 1997;277:1656-1659.
36. Kim Y, Lee S, Kim S, Kim D, Ahn J-H, Ahn K. Human cytomegalovirus clinical strain-specific microRNA miR-UL148D targets the human chemokine RANTES during infection. PLoS Pathog 2012;8:e1002577.
37. Arvanitakis L, Geras-Raaka E, Varma A, Gershengorn MC, Cesarman E. Human herpesvirus KSHV encodes a constitutively active G-protein-coupled receptor linked to cell proliferation. Nature 1997;385:347-350.
38. Smith P, et al. Schistosoma mansoni secretes a chemokine binding protein with antiinflammatory activity. J Exp Med 2005;202:1319-1325.
39. Déruaz M, et al. Ticks produce highly selective chemokine binding proteins with antiinflammatory activity. J Exp Med 2008;205:2019-2031.
40. Berkel V van, et al. Identification of a gammaherpesvirus selective chemokine binding protein that inhibits chemokine action. J Virol 2000;74:6741-6747.
41. Parry CM, et al. A broad spectrum secreted chemokine binding protein encoded by a herpesvirus. J Exp Med 2000;191:573-578.
42. Pyo R, et al. Inhibition of intimal hyperplasia in transgenic mice conditionally expressing the chemokine-binding protein M3. Am J Pathol 2004;164:2289-2297.
43. Liu L, et al. Viral chemokine-binding proteins inhibit inflammatory responses and aortic allograft transplant vasculopathy in rat models. Transplantation 2004;77:1652-1660.
44. Dabbagh K, et al. Local blockade of allergic airway hyperreactivity and inflammation by the poxvirus-derived pan-CC-chemokine inhibitor vCCI. J Immunol 2000;165:3418-3422.
45. Jensen KK, et al. Disruption of CCL21-induced chemotaxis in vitro and in vivo by M3, a chemokine-binding protein encoded by murine gammaherpesvirus 68. J Virol 2003;77:624-630.
46. Martin AP, et al. The chemokine binding protein M3 prevents diabetes induced by multiple low doses of streptozotocin. J Immunol 2007;178:4623-4631.
47. Alexander JM, et al. Structural basis of chemokine sequestration by a herpesvirus decoy receptor. Cell 2002;111:343-356.
48. Alexander-Brett JM, Fremont DH. Dual GPCR and GAG Mimicry by the M3 Chemokine Decoy Receptor. J Exp Med 2007;204:3157-3172.
49. Bryant NA, Davis-Poynter N, Vanderplasschen A, Alcami A. Glycoprotein G isoforms from some alphaherpesviruses function as broad-spectrum chemokine binding proteins. EMBO J 2003;22:833-846.
50. Viejo-Borbolla A, et al. Enhancement of chemokine function as an immunomodulatory strategy employed by human herpesviruses. PLoS Pathog 2012;8:e1002497.
51. Wang D, Bresnahan W, Shenk T. Human cytomegalovirus encodes a highly specific RANTES decoy receptor. Proc Natl Acad Sci USA 2004;101:16642-16647.
52. Appay V, Rowland-Jones SL. RANTES: a versatile and controversial chemokine. Trends Immunol 2001;22:83-87.
53. Bresnahan WA, Shenk T. A subset of viral transcripts packaged within human cytomegalovirus particles. Science 2000;288:2373-2376.
54. Graham KA, et al. The T1/35kDa family of poxvirus-secreted proteins bind chemokines and modulate leukocyte influx into virus-infected tissues. Virology 1997;229:12-24.
55. Smith CA, et al. Poxvirus genomes encode a secreted, soluble protein that preferentially inhibits beta chemokine activity yet lacks sequence homology to known chemokine receptors. Virology 1997;236:316-327.
56. Alcamí A, Symons JA, Collins PD, Williams TJ, Smith GL. Blockade of chemokine activity by a soluble chemokine binding protein from vaccinia virus. J Immunol 1998;160:624-633.
57. Lalani AS, Masters J, Graham K, Liu L, Lucas A, McFadden G. Role of the myxoma virus soluble CC-chemokine inhibitor glycoprotein, M-T1, during myxoma virus pathogenesis. Virology 1999;256:233-245.
58. Reading PC, Symons JA, Smith GL. A soluble chemokine-binding protein from vaccinia virus reduces virus virulence and the inflammatory response to infection. J Immunol 2003;170:1435-1442.
59. Carfí A, Smith CA, Smolak PJ, McGrew J, Wiley DC. Structure of a soluble secreted chemokine inhibitor vCCI (p35) from cowpox virus. Proc Natl Acad Sci USA 1999;96:12379-12383.
60. Arnold PL, Fremont DH. Structural Determinants of Chemokine Binding by an Ectromelia Virus-Encoded Decoy Receptor. J Virol 2006;80:7439-7449.
61. Zhang L, et al. Solution structure of the complex between poxvirus-encoded CC chemokine inhibitor vCCI and human MIP-1beta. Proc Natl Acad Sci USA 2006;103:13985-13990.
62. Beck CG, Studer C, Zuber JF, Demange BJ, Manning U, Urfer R. The viral CC chemokine-binding protein vCCI inhibits monocyte chemoattractant protein-1 activity by masking its CCR2B-binding site. J Biol Chem 2001;276:43270-43276.
63. Seet BT, Singh R, Paavola C, Lau EK, Handel TM, McFadden G. Molecular determinants for CC-chemokine recognition by a poxvirus CC-chemokine inhibitor. Proc Natl Acad Sci USA 2001;98:9008-9013.
64. Bahar MW, et al. Structure and function of A41, a vaccinia virus chemokine binding protein. PLoS Pathog 2008;4:e5.
65. Ruiz-Argüello MB, et al. An ectromelia virus protein that interacts with chemokines through their glycosaminoglycan binding domain. J Virol 2008;82:917-926.
66. Alejo A, Ruiz-Argüello MB, Ho Y, Smith VP, Saraiva M, Alcami A. A chemokine-binding domain in the tumor necrosis factor receptor from variola (smallpox) virus. Proc Natl Acad Sci USA 2006;103:5995-6000.
67. Antonets DV, Nepomnyashchikh TS, Shchelkunov SN. SECRET domain of variola virus CrmB protein can be a member of poxviral type II chemokine-binding proteins family. BMC Res Notes 2010;3:271.
68. Xue X, et al. Structural basis of chemokine sequestration by CrmD, a poxvirus-encoded tumor necrosis factor receptor. PLoS Pathog 2011;7:e1002162.
69. Idriss HT, Naismith JH. TNF alpha and the TNF receptor superfamily: structure-function relationship(s). Microsc Res Tech 2000;50:184-195.
70. Dempsey PW, Doyle SE, He JQ, Cheng G. The signaling adaptors and pathways activated by TNF superfamily. Cytokine Growth Factor Rev 2003;14:193-209.
71. Kircheis R, Milleck J, Korobko VG, Shingarova LN, Schmidt HE. Differences in the biological activity of TNF alpha and TNF beta correlate with their different abilities for binding to the target cells. Eur Cytokine Netw 1992;3:381-390.
72. Sedý JR, Spear PG, Ware CF. Cross-regulation between herpesviruses and the TNF superfamily members. Nat Rev Immunol 2008;8:861-873.
73. Turner SJ, Silke J, Kenshole B, Ruby J. Characterization of the ectromelia virus serpin, SPI-2. J Gen Virol 2000;81:2425-2430.
74. Thome M, et al. Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors. Nature 1997;386:517-521.
75. Skaletskaya A, Bartle LM, Chittenden T, McCormick AL, Mocarski ES, Goldmacher VS. A cytomegalovirus-encoded inhibitor of apoptosis that suppresses caspase-8 activation. Proc Natl Acad Sci USA 2001;98:7829-7834.
76. Brinkmann MM, Schulz TF. Regulation of intracellular signalling by the terminal membrane proteins of members of the Gammaherpesvirinae. J Gen Virol 2006;87:1047-1074.
77. Bristol JA, Robinson AR, Barlow EA, Kenney SC. The Epstein-Barr virus BZLF1 protein inhibits tumor necrosis factor receptor 1 expression through effects on cellular C/EBP proteins. J Virol 2010;84:12362-12374.
78. Morrison TE, Mauser A, Klingelhutz A, Kenney SC. Epstein-Barr virus immediate-early protein BZLF1 inhibits tumor necrosis factor alpha-induced signaling and apoptosis by downregulating tumor necrosis factor receptor 1. J Virol 2004;78:544-549.
79. Alcami A. Viral mimicry of cytokines, chemokines and their receptors. Nat Rev Immunol 2003;3:36-50.
80. Rahman MM, McFadden G. Modulation of tumor necrosis factor by microbial pathogens. PLoS Pathog 2006;2:e4.
81. Smith CA, et al. A receptor for tumor necrosis factor defines an unusual family of cellular and viral proteins. Science 1990;248:1019-1023.
82. Hu FQ, Smith CA, Pickup DJ. Cowpox virus contains two copies of an early gene encoding a soluble secreted form of the type II TNF receptor. Virology 1994;204:343-356.
83. Smith CA, et al. Cowpox virus genome encodes a second soluble homologue of cellular TNF receptors, distinct from CrmB, that binds TNF but not LT alpha. Virology 1996;223:132-147.
84. Loparev VN, et al. A third distinct tumor necrosis factor receptor of orthopoxviruses. Proc Natl Acad Sci USA 1998;95:3786-3791.
85. Saraiva M, Alcami A. CrmE, a novel soluble tumor necrosis factor receptor encoded by poxviruses. J Virol 2001;75:226-233.
86. Shibata H, et al. Creation and X-ray structure analysis of the tumor necrosis factor receptor-1-selective mutant of a tumor necrosis factor-alpha antagonist. J Biol Chem 2008;283:998-1007.
87. Alejo A, Pontejo SM, Alcami A. Poxviral TNFRs: properties and role in viral pathogenesis. Adv Exp Med Biol 2011;691:203-210.
88. Banner DW, et al. Crystal structure of the soluble human 55 kd TNF receptor-human TNF beta complex: implications for TNF receptor activation. Cell 1993;73:431-445.
89. Mukai Y, et al. Solution of the structure of the TNF-TNFR2 complex. Sci Signal 2010;3:ra83.
90. Hymowitz SG, et al. Triggering cell death: the crystal structure of Apo2L/TRAIL in a complex with death receptor 5. Mol Cell 1999;4:563-571.
91. Graham SC, Bahar MW, Abrescia NGA, Smith GL, Stuart DI, Grimes JM. Structure of CrmE, a virus-encoded tumour necrosis factor receptor. J Mol Biol 2007;372:660-671.
92. Loetscher H, Stueber D, Banner D, Mackay F, Lesslauer W. Human tumor necrosis factor alpha (TNF alpha) mutants with exclusive specificity for the 55-kDa or 75-kDa TNF receptors. J Biol Chem 1993;268:26350-26357.
93. Brunetti CR, et al. A secreted high-affinity inhibitor of human TNF from Tanapox virus. Proc Natl Acad Sci USA 2003;100:4831-4836.
94. Rahman MM, Barrett JW, Brouckaert P, McFadden G. Variation in ligand binding specificities of a novel class of poxvirus-encoded tumor necrosis factor-binding protein. J Biol Chem 2006;281:22517-22526.
95. Yang Z, West AP, Bjorkman PJ. Crystal structure of TNFα complexed with a poxvirus MHC-related TNF binding protein. Nat Struct Mol Biol 2009;16:1189.
96. Horie R, Watanabe T. CD30: expression and function in health and disease. Semin Immunol 1998;10:457-470.
97. Smith CA, et al. CD30 antigen, a marker for Hodgkin's lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology to TNF. Cell 1993;73:1349-1360.
98. Panus JF, Smith CA, Ray CA, Smith TD, Patel DD, Pickup DJ. Cowpox virus encodes a fifth member of the tumor necrosis factor receptor family: a soluble, secreted CD30 homologue. Proc Natl Acad Sci USA 2002;99:8348-8353.
99. Saraiva M, Smith P, Fallon PG, Alcami A. Inhibition of type 1 cytokine-mediated inflammation by a soluble CD30 homologue encoded by ectromelia (mousepox) virus. J Exp Med 2002;196:829-839.
100. Alejo A, et al. A method for the generation of ectromelia virus (ECTV) recombinants: in vivo analysis of ECTV vCD30 deletion mutants. PLoS ONE 2009;4:e5175.
101. Weber A, Wasiliew P, Kracht M. Interleukin-1 (IL-1) pathway. Sci Signal 2010;3:cm1.
102. Arend WP, Palmer G, Gabay C. IL-1, IL-18, and IL-33 families of cytokines. Immunol Rev 2008;223:20-38.
103. Subramaniam S, Stansberg C, Cunningham C. The interleukin 1 receptor family. Dev Comp Immunol 2004;28:415-428.
104. Symons JA, Eastgate JA, Duff GW. Purification and characterization of a novel soluble receptor for interleukin 1. J Exp Med 1991;174:1251-1254.
105. Gutcher I, Urich E, Wolter K, Prinz M, Becher B. Interleukin 18-independent engagement of interleukin 18 receptor-alpha is required for autoimmune inflammation. Nat Immunol 2006;7:946-953.
106. Dinarello CA. Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol 2009;27:519-550.
107. Dinarello CA. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood 2011;117:3720-3732.
108. Ray CA, et al. Viral inhibition of inflammation: cowpox virus encodes an inhibitor of the interleukin-1 beta converting enzyme. Cell 1992;69:597-604.
109. Bahar MW, et al. How vaccinia virus has evolved to subvert the host immune response. J Struct Biol 2011;175:127-134.
110. Nazarian SH, et al. Yaba monkey tumor virus encodes a functional inhibitor of interleukin-18. J Virol 2008;82:522-528.
111. Xiang Y, Moss B. IL-18 binding and inhibition of interferon gamma induction by human poxvirus-encoded proteins. Proc Natl Acad Sci USA 1999;96:11537-11542.
112. Calderara S, Xiang Y, Moss B. Orthopoxvirus IL-18 binding proteins: affinities and antagonist activities. Virology 2001;279:22-26.
113. Born TL, et al. A poxvirus protein that binds to and inactivates IL-18, and inhibits NK cell response. J Immunol 2000;164:3246-3254.
114. Sims JE. IL-1 and IL-18 receptors, and their extended family. Curr Opin Immunol 2002;14:117-122.
115. Kimura T, Kato Z, Ohnishi H, Tochio H, Shirakawa M, Kondo N. Expression, purification and structural analysis of human IL-18 binding protein: a potent therapeutic molecule for allergy. Allergol Int 2008;57:367-376.
116. Naftali T, Novick D, Gabay G, Rubinstein M, Novis B. Interleukin-18 and its binding protein in patients with inflammatory bowel disease during remission and exacerbation. Isr Med Assoc J 2007;9:504-508.
117. Krumm B, Meng X, Li Y, Xiang Y, Deng J. Structural basis for antagonism of human interleukin 18 by poxvirus interleukin 18-binding protein. Proc Natl Acad Sci USA 2008;105:20711-20715.
118. Dinarello C. Targeting interleukin 18 with interleukin 18 binding protein. Ann Rheum Dis 2000;59:i17-i20.
119. Smith GL, Chan YS. Two vaccinia virus proteins structurally related to the interleukin-1 receptor and the immunoglobulin superfamily. J Gen Virol 1991;72(Pt 3):511-518.
120. Alcamí A, Smith GL. A mechanism for the inhibition of fever by a virus. Proc Natl Acad Sci USA 1996;93:11029-11034.
121. Vigers GP, Anderson LJ, Caffes P, Brandhuber BJ. Crystal structure of the type-I interleukin-1 receptor complexed with interleukin-1beta. Nature 1997;386:190-194.
122. Schreuder H, et al. A new cytokine-receptor binding mode revealed by the crystal structure of the IL-1 receptor with an antagonist. Nature 1997;386:194-200.
123. Vigers GP, Dripps DJ, Edwards CK, 3rd, Brandhuber BJ. X-ray crystal structure of a small antagonist peptide bound to interleukin-1 receptor type 1. J Biol Chem 2000;275:36927-36933.
124. Notredame C, Higgins DG, Heringa J. T-Coffee: a novel method for fast and accurate multiple sequence alignment. J Mol Biol 2000;302:205-217.
125. Spriggs MK, et al. Vaccinia and cowpox viruses encode a novel secreted interleukin-1-binding protein. Cell 1992;71:145-152.
126. Isaacs A, Lindenmann J. Virus interference. I. The interferon. Proc R Soc Lond B Biol Sci 1957;147:258-267.
127. Samuel CE. Antiviral actions of interferons. Clin Microbiol Rev 2001;14:778-809, table of contents.
128. Katze MG, He Y, Gale M, Jr. Viruses and interferon: a fight for supremacy. Nat Rev Immunol 2002;2:675-687.
129. Sen GC. Viruses and interferons. Annu Rev Microbiol 2001;55:255-281.
130. Biron CA. Initial and innate responses to viral infections-pattern setting in immunity or disease. Curr Opin Microbiol 1999;2:374-381.
131. Langer JA, Cutrone EC, Kotenko S. The Class II cytokine receptor (CRF2) family: overview and patterns of receptor-ligand interactions. Cytokine Growth Factor Rev 2004;15:33-48.
132. Thomas C, et al. Structural linkage between ligand discrimination and receptor activation by type I interferons. Cell 2011;146:621-632.
133. Platanias LC. Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat Rev Immunol 2005;5:375-386.
134. Grandvaux N, tenOever BR, Servant MJ, Hiscott J. The interferon antiviral response: from viral invasion to evasion. Curr Opin Infect Dis 2002;15:259-267.
135. Renauld J-C. Class II cytokine receptors and their ligands: key antiviral and inflammatory modulators. Nat Rev Immunol 2003;3:667-676.
136. Bach EA, et al. Ligand-induced assembly and activation of the gamma interferon receptor in intact cells. Mol Cell Biol 1996;16:3214-3221.
137. Shtrichman R, Samuel CE. The role of gamma interferon in antimicrobial immunity. Curr Opin Microbiol 2001;4:251-259.
138. Josephson K, Logsdon NJ, Walter MR. Crystal Structure of the IL-10/IL-10R1 Complex Reveals a Shared Receptor Binding Site. Immunity 2001;15:35-46.
139. Miknis ZJ, Magracheva E, Li W, Zdanov A, Kotenko SV, Wlodawer A. Crystal structure of human interferon-λ1 in complex with its high-affinity receptor interferon-λR1. J Mol Biol 2010;404:650-664.
140. Yoon S-I, et al. Structure and mechanism of receptor sharing by the IL-10R2 common chain. Structure 2010;18:638-648.
141. Uzé G, Monneron D. IL-28 and IL-29: newcomers to the interferon family. Biochimie 2007;89:729-734.
142. Sommereyns C, Paul S, Staeheli P, Michiels T. IFN-lambda (IFN-lambda) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo. PLoS Pathog 2008;4:e1000017.
143. Witte K, et al. Despite IFN-|[lambda]| receptor expression, blood immune cells, but not keratinocytes or melanocytes, have an impaired response to type III interferons: implications for therapeutic applications of these cytokines. Genes Immun 2009;10:702-714.
144. Smith VP, Alcami A. Inhibition of interferons by ectromelia virus. J Virol 2002;76:1124-1134.
145. Waibler Z, et al. Vaccinia virus-mediated inhibition of type I interferon responses is a multifactorial process involving the soluble type I interferon receptor B18 and intracellular components. J Virol 2009;83:1563-1571.
146. Alcamí A, Symons JA, Smith GL. The vaccinia virus soluble alpha/beta interferon (IFN) receptor binds to the cell surface and protects cells from the antiviral effects of IFN. J Virol 2000;74:11230-11239.
147. Colamonici OR, Domanski P, Sweitzer SM, Larner A, Buller RM. Vaccinia virus B18R gene encodes a type I interferon-binding protein that blocks interferon alpha transmembrane signaling. J Biol Chem 1995;270:15974-15978.
148. Xu R-H, et al. The orthopoxvirus type I IFN binding protein is essential for virulence and an effective target for vaccination. J Exp Med 2008;205:981-992.
149. Meager A, Visvalingam K, Dilger P, Bryan D, Wadhwa M. Biological activity of interleukins-28 and -29: comparison with type I interferons. Cytokine 2005;31:109-118.
150. Ank N, et al. An important role for type III interferon (IFN-lambda/IL-28) in TLR-induced antiviral activity. J Immunol 2008;180:2474-2485.
151. Bartlett NW, Buttigieg K, Kotenko SV, Smith GL. Murine interferon lambdas (type III interferons) exhibit potent antiviral activity in vivo in a poxvirus infection model. J Gen Virol 2005;86:1589-1596.
152. Huang J, et al. Inhibition of type I and type III interferons by a secreted glycoprotein from Yaba-like disease virus. Proc Natl Acad Sci USA 2007;104:9822-9827.
153. Lee HJ, Essani K, Smith GL. The genome sequence of Yaba-like disease virus, a yatapoxvirus. Virology 2001;281:170-192.
154. Nuara AA, et al. Structure and mechanism of IFN-gamma antagonism by an orthopoxvirus IFN-gamma-binding protein. Proc Natl Acad Sci USA 2008;105:1861-1866.
155. Nuara AA, Bai H, Chen N, Buller RML, Walter MR. The unique C termini of orthopoxvirus gamma interferon binding proteins are essential for ligand binding. J Virol 2006;80:10675-10682.
156. Nuara AA, Buller RML, Bai H. Identification of residues in the ectromelia virus gamma interferon-binding protein involved in expanded species specificity. J Gen Virol 2007;88:51-60.
157. Mossman K, Upton C, Buller RM, McFadden G. Species specificity of ectromelia virus and vaccinia virus interferon-gamma binding proteins. Virology 1995;208:762-769.
158. Mossman K, Upton C, McFadden G. The myxoma virus-soluble interferon-gamma receptor homolog, M-T7, inhibits interferon-gamma in a species-specific manner. J Biol Chem 1995;270:3031-3038.
159. Pestka S, Langer JA, Zoon KC, Samuel CE. Interferons and their Actions. Annu Rev Biochem 1987;56:727-777.
160. Fountoulakis M, et al. Purification and biochemical characterization of a soluble mouse interferon-gamma receptor produced in insect cells. Eur J Biochem 1991;198:441-450.
161. Sakala IG, et al. Poxvirus-Encoded Gamma Interferon Binding Protein Dampens the Host Immune Response to Infection. J Virol 2007;81:3346-3353.
162. Walter MR, et al. Crystal structure of a complex between interferon-gamma and its soluble high-affinity receptor. Nature 1995;376:230-235.
163. Thiel DJ, et al. Observation of an unexpected third receptor molecule in the crystal structure of human interferon-gamma receptor complex. Structure 2000;8:927-936.
164. Randal M, Kossiakoff AA. The structure and activity of a monomeric interferon-gamma:alpha-chain receptor signaling complex. Structure 2001;9:155-163.
165. Haelewyn J, Michiels L, Verhaert P, Hoylaerts MF, Witters R, Ley MD. Interaction of truncated human interferon gamma variants with the interferon gamma receptor: crucial importance of Arg-129. Biochem J 1997;324(Pt 2):591-595.
166. Lundell D, Lunn CA, Senior MM, Zavodny PJ, Narula SK. Importance of the loop connecting A and B helices of human interferon-gamma in recognition by interferon-gamma receptor. J Biol Chem 1994;269:16159-16162.
167. Liu L, et al. The viral anti-inflammatory chemokine-binding protein M-T7 reduces intimal hyperplasia after vascular injury. J Clin Invest 2000;105:1613-1621.
168. Viejo-Borbolla A, et al. Attenuation of TNF-driven murine ileitis by intestinal expression of the viral immunomodulator CrmD. Mucosal Immunol 2010;3:633-644.